TOP > 外国特許検索 > METHOD FOR PREDICTING IMMUNE-RELATED SIDE EFFECT IN USE OF IMMUNE-CHECKPOINT INHIBITING DRUG

METHOD FOR PREDICTING IMMUNE-RELATED SIDE EFFECT IN USE OF IMMUNE-CHECKPOINT INHIBITING DRUG

外国特許コード F180009358
整理番号 (S2016-0892-N0)
掲載日 2018年4月19日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2017JP024244
国際公開番号 WO 2018003995
国際出願日 平成29年6月30日(2017.6.30)
国際公開日 平成30年1月4日(2018.1.4)
優先権データ
  • 特願2016-131913 (2016.7.1) JP
発明の名称 (英語) METHOD FOR PREDICTING IMMUNE-RELATED SIDE EFFECT IN USE OF IMMUNE-CHECKPOINT INHIBITING DRUG
発明の概要(英語) The present invention provides a new method for acquiring data for predicting the development of a side effect caused by administration of at least one antibody drug selected from anti-PD-1 antibody, anti-PD-L1 antibody, anti-CTLA4 antibody, and antigen-binding fragments thereof, or provides a new method for predicting the development of said side effect. In more detail, the present invention provides a method for acquiring data for predicting the development of a side effect or a method for predicting the development of said side effect, including measuring a level of at least one marker selected from sCD163 and CXCL5 in a biological sample collected from a subject administered with the aforementioned antibody drugs.
特許請求の範囲(英語) [claim1]
1. Anti-PD-1 antibody, anti-PD-L1 antibody, anti-CTLA4 antibody and an antigen-binding fragments thereof at least one antibody selected from pharmaceutical due to the administration of side effects in order to predict the onset of a method for obtaining data, wherein the antibody is administered drug in a biological sample obtained from the subject in the at least one material selected from sCD163 CXCL5 and the level of the marker comprises measuring, method.
[claim2]
2. Wherein the antibody is anti-PD-1 nivolumab, method according to claim 1.
[claim3]
3. Wherein the antibody is anti-CTLA4 ipilimumab, method according to claim 1 or 2.
[claim4]
4. Wherein the antibody is anti-cancer agent is a pharmaceutical, the method of any one of claims 1-3.
[claim5]
5. Said side effects in an immune-related adverse effects, according to any one of claims 1-4 to.
[claim6]
6. Wherein a combination of markers and CXCL5 sCD163, method according to any one of claims 1-5.
[claim7]
7. The method of administration of the drug in a biological sample taken from the level of the marker and, obtained from the subject prior to administration of the pharmaceutical according to the invention is in the biological sample, the level of the marker corresponding to the comparison comprises data can be acquired, wherein the method of any one of claims 1-6.
[claim8]
8. The method of administration of the drug in a biological sample taken from the level of the marker of the data or the comparison, developing a side effect indicator, method according to claim 7.
[claim9]
9. The method of administration of the drug in a biological sample taken from the level of the marker or the compared data, administering to a subject index Ecdysteroids, method according to claim 7.
[claim10]
10. Comparing said data indicative of developing side effects, method according to claim 8 or 9.
[claim11]
11. Anti-PD-1 antibody, anti-PD-L1 antibody, anti-CTLA4 antibody and an antigen-binding fragments thereof at least one antibody selected from pharmaceutical due to the administration of a method for predicting onset of side effects, the administration of the pharmaceutical according to the invention to which has been taken from a biological sample from the at least one material selected from sCD163 CXCL5 and in the level of the marker comprises measuring, method.
[claim12]
12. Anti-PD-1 antibody, anti-PD-L1 antibody, anti-CTLA4 antibody and an antigen-binding fragments thereof at least one antibody selected from pharmaceutical due to the administration of a method of monitoring the effects, wherein said antibody is the administration of the medicament in a biological sample collected from at least one material selected from the sCD163 CXCL5 and measuring the level of a marker comprising, method.
[claim13]
13. Anti-PD-1 antibody, anti-PD-L1 antibody, anti-CTLA4 antibody and an antigen-binding fragments thereof is selected from at least one antibody in the administration of the medicament, pharmaceutical due to the administration of the antibody in order to predict the onset of side effects, comprising sCD163 CXCL5 or marker.
[claim14]
14. Anti-PD-1 antibody, anti-PD-L1 antibody, anti-CTLA4 antibody and an antigen-binding fragments thereof at least one antibody selected from pharmaceutical due to the administration of side effects for predicting the onset of the disease, anti-sCD163 antibody, anti-CXCL5 antibody and antigen-binding fragments thereof at least one component selected from the group consisting of a diagnostic agent.
[claim15]
15. Anti-PD-1 antibody, anti-PD-L1 antibody, anti-CTLA4 antibody and an antigen-binding fragments thereof at least one antibody selected from the dispensing of the medicament for the prediction of the onset of a side effect derived, anti-sCD163 antibody, anti-CXCL5 antibody and antigen-binding fragments thereof is selected from at least one component of a kit for diagnosing comprising.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • TOHOKU UNIVERSITY
  • 発明者(英語)
  • FUJIMURA TAKU
国際特許分類(IPC)
指定国 (WO201803995)
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記「問合せ先」までご連絡ください。

PAGE TOP

close
close
close
close
close
close